Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD

Blood

Volumn 122, Issue 25, 2013, Pages 4111-4118

  Olivieri, Attilio ^a   Cimminiello, Michele ^b   Corradini, Paolo ^c   Mordini, Nicola ^d   Fedele, Roberta ^e   Selleri, Carmine ^f   Onida, Francesco ^g   Patriarca, Francesca ^h   Pavone, Enzo ⁱ   Svegliati, Silvia ^a   Gabrielli, Armando ^a   Bresciani, Paola ^j   Nuccorini, Roberta ^b   Pascale, Sara ^b   Coluzzi, Sabrina ^b   Pane, Fabrizio ^k   Poloni, Antonella ^a   Olivieri, Jacopo ^a   Leoni, Pietro ^a   Bacigalupo, Andrea ^l  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b Azienda Ospedaliera Regionale San Carlo   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d S CROCE E CARLE HOSPITAL   (Italy)

^e BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^f UNIVERSITY OF SALERNO   (Italy)

^g FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^h SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

ⁱ Azienda Ospedaliera Card G Panico   (Italy)

^j UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^k UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^l UNIVERSITY OF GENOA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; STEROID;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FATIGUE; FEMALE; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; MULTICENTER STUDY; MYALGIA; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NATIONAL HEALTH ORGANIZATION; NATIONAL INSTITUTES OF HEALTH CRITERIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFRACTORY PERIOD; STEROID REFRACTORY CHRONIC GRAFT VERSUS HOST DISEASE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VALIDATION STUDY; WEAKNESS;

EID: 84891318859     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-05-494278     Document Type: Article

References (33)

1. Wolff D, Schleuning M, von Harsdorf S, et al. Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2011;17(1): 1-17.
2. Arai S, Jagasia M, Storer B, et al. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood. 2011;118(15): 4242-4249.
3. Pidala J, Kurland B, Chai X, et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood. 2011;117(17): 4651-4657.
4. Jacobsohn DA, Kurland BF, Pidala J, et al. Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. Blood. 2012; 120(13): 2545-2552, quiz 2774.
5. Martires KJ, Baird K, Steinberg SM, et al. Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease. Blood. 2011;118(15): 4250-4257.
6. Inamoto Y, Storer BE, Petersdorf EW, et al. Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease. Blood. 2013;121(25): 5098-5103.
7. Flowers ME, Apperley JF, van Besien K, et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood. 2008;112(7): 2667-2674.
8. Jacobsohn DA, Chen AR, Zahurak M, et al. Study of pentostatin in patients with corticosteroidrefractory chronic graft-versus-host disease. J Clin Oncol. 2007;25(27): 4255-4261. (Pubitemid 47548565)
9. Olivieri A, Locatelli F, Zecca M, et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood. 2009;114(3): 709-718.
10. Magro L, Mohty M, Catteau B, et al. Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood. 2009;114(3): 719-722.
11. Stadler M, Ahlborn R, Kamal H, et al. Limited efficacy of imatinib in severe pulmonary chronic graft-versus-host disease. Blood. 2009;114(17): 3718-3719, author reply 3719-3720.
12. Chen GL, Arai S, Flowers ME, et al. A phase 1 study of imatinib for corticosteroid-dependent/ refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. Blood. 2011;118(15): 4070-4078.
13. de Masson A, Bouaziz JD, Peffault de Latour R, et al. Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD. Blood. 2012;120(25): 5089-5090.
14. Akhmetshina A, Dees C, Pileckyte M, et al. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J. 2008;22(7): 2214-2222. (Pubitemid 351948641)
15. Olivieri J, Coluzzi S, Attolico I, Olivieri A. Tirosin kinase inhibitors in chronic graft versus host disease: from bench to bedside. ScientificWorldJournal. 2011;11: 1908-1931.
16. McCormick LL, Zhang Y, Tootell E, Gilliam AC. Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versushost disease: a model for human scleroderma. J Immunol. 1999;163(10): 5693-5699.
17. Baroni SS, Santillo M, Bevilacqua F, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med. 2006; 354(25): 2667-2676.
18. Svegliati S, Olivieri A, Campelli N, et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood. 2007;110(1): 237-241. (Pubitemid 47026840)
19. Seggewiss R, Loré K, Greiner E, et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood. 2005;105(6): 2473-2479. (Pubitemid 40387048)
20. Miyachi K, Ihara A, Hankins RW, Murai R, Maehiro S, Miyashita H. Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia. Clin Rheumatol. 2003; 22(4-5): 329-332. (Pubitemid 37483630)
21. Pavletic SZ, Martin P, Lee SJ, et al; Response Criteria Working Group. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant. 2006;12(3): 252-266. (Pubitemid 43273710)
22. Couriel DR, Hosing C, Saliba R, et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood. 2006;107(8): 3074-3080.
23. Couriel DR, Saliba R, Escalón MP, et al. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versushost disease. Br J Haematol. 2005;130(3): 409-417. (Pubitemid 43899590)
24. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12): 945-956. (Pubitemid 41754712)
25. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1): 1-10. (Pubitemid 19099520)
26. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6): 695-706. (Pubitemid 29126745)
27. Inamoto Y, Storer BE, Lee SJ, et al. Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. Blood. 2013; 121(12): 2340-2346.
28. Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006;108(2): 756-762. (Pubitemid 44061381)
29. Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011;365(22): 2055-2066.
30. Lee SJ, Vogelsang G, Flowers ME. Chronic graftversus- host disease. Biol Blood Marrow Transplant. 2003;9(4): 215-233.
31. Jagasia M, Giglia J, Chinratanalab W, et al. Incidence and outcome of chronic graft-versushost disease using National Institutes of Health consensus criteria. Biol Blood Marrow Transplant. 2007;13(10): 1207-1215. (Pubitemid 47413020)
32. Cho BS, Min CK, Eom KS, et al. Feasibility of NIH consensus criteria for chronic graft-versus-host disease. Leukemia. 2009;23(1): 78-84.
33. Mitchell SA, Jacobsohn D, Thormann Powers KE, et al. A multicenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable change. Biol Blood Marrow Transplant. 2011;17(11): 1619-1629.